Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report) on January 18 and set a price target of $10.00. The company’s shares opened today at $3.87.
According to TipRanks, Catanzaro is a 4-star analyst with an average return of 4.0% and a 38.43% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Keros Therapeutics, and Biomea Fusion.
Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $12.00.
See the top stocks recommended by analysts >>
OCUL market cap is currently $424.3M and has a P/E ratio of -3.46.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OCUL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix (OCUL) Company Description:
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Read More on OCUL:
- Summer Road raises Ocular Therapeutix stake by $5.0M
- Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Ocular Therapeutix 30.8M share Spot Secondary priced at $3.25
- Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
- Ocular Therapeutix $100M Spot Secondary; re-offered at $3.25
